Patent: 9,284,556
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Summary for Patent: 9,284,556
Title: | Methods for the treatment of hepatitis B and hepatitis D infections |
Abstract: | It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function. |
Inventor(s): | Bazinet; Michel (Montreal, CA), Vaillant; Andrew (Roxboro, CA) |
Assignee: | |
Application Number: | 14/449,174 |
Patent Claims: | see list of patent claims |
Details for Patent 9,284,556
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | ⤷ Sign Up | 2032-08-30 |
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Sign Up | 2032-08-30 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Sign Up | 2032-08-30 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Sign Up | 2032-08-30 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 03/07/2002 | ⤷ Sign Up | 2032-08-30 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/17/2004 | ⤷ Sign Up | 2032-08-30 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/21/2012 | ⤷ Sign Up | 2032-08-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |